Metformin in obesity, cancer and aging: addressing controversies.
Authors: Berstein LM
Abstract
Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan. Gradually accumulating discrepancies about its effect on cancer and obesity can be explained by the shortage of randomized clinical trials, differences between control groups (reference points), gender- and age-associated effects and pharmacogenetic factors. Studies of the potential antiaging effects of antidiabetic biguanides, such as metformin, are still experimental for obvious reasons and their results are currently ambiguous. Here we discuss whether the discrepancies in different studies are merely methodological or inherently related to individual differences in responsiveness to...
AxSys provides NHS with enhanced clinical IT platform
AxSys Technology has unveiled its enhanced Excelicare clinical IT platform to provide NHS Trusts and primary care providers with a cost-effective way to build patient records electronically.
read more (Source: Healthcare IT News)div id=medwormpbiMedWorm Sponsor Message:/i/b Have a look at a href=http://www.thepsychologydaily.comThe Psychology Daily/a, the new psychology portal powered by MedWorm, with all the latest psychology news and research updated daily./p/div